Pyrosequencing Quality Control
All samples were run in duplicate with methylation standards: highly and lowly methylated human genomic control standards for LUMA (EpigenDx, Hopkinton, MA) and Epitect 100% and 0% methylated controls (Qiagen) for all other gene loci. Pyrosequencing was run in two batches due to timing of participant consent in the study. There was no statistical difference in mean methylation status of candidate genes between batches. Global methylation, LUMA and LINE1, varied by batch (p < 0.001) but birth gender and birth weight were similar within the batches. Thus, raw methylation values were used in bivariate analyses reported in this manuscript, but future multivariable analyses utilizing this data should also adjust for batch. Percent methylation at each CpG site was averaged between duplicate runs for a final measure used in analyses. Mean methylation at all measured CpG sites in gene promoters was calculated and compared to patterns of methylation at individual CpG sites within each gene. There was significant variability between methylation status at each CpG site within an amplicon and they correlated differently with metabolites and methylation at other genes of interest; therefore, all analyses were run including individual CpG sites for each candidate loci.
LUMA Assay
The Luminometric Methylation Assay (LUMA) uses restriction enzymes to digest genomic DNA and detects methylation at 5'-CCGG-3' sequences across the genome. A detailed description of LUMA analysis via pyrosequencing has been described previously (7, 26) . Methylation insensitive MspI (Biolabs, Ipswich, MA) and methylation sensitive HpaII (Biolabs) enzymes are added to 300 ng of genomic DNA with internal standard EcoR1 (Biolabs) enzyme and 10x Buffer Tango TM with BSA (Fermentas, Grand Island, NY) for differential digestion. To facilitate digestion, samples were incubated for four hours at 37 o C. PyroMarkMD software is run with the following nucleotide dispensation: GTGTCACATGTGTG. Global DNA methylation is calculated by the ratio of normalized product signal between methylation sensitive and insensitive digestions from the same sample: 1-[(HpaII/EcoR1) / (MspI/EcoR1)] x 100.
Statistical Analyses
Repeated Maternal Measures. Plasma metabolites were right skewed, so median and interquartile range (IQR) were used to compare M1 and M2 levels, and significance was tested via non-parametric Wilcoxon Signed Rank test (Table S1 ). Methylation status of CpG sites in the promoter region of global and candidate gene loci of interest were normally distributed. Thus, comparisons were made between mean and standard deviation at M1 and M2; tested via Paired T-test (Table S3) . Significance for both tests of central tendency was determined by a p-value < 0.05.
Bivariate Correlation Analysis. Multiple levels of statistical analyses were performed to fully understand the complex relationships between metabolites and DNA methylation. Simple bivariate correlations (Kendall's Tau) were used to compare metabolome and methylome in the three sample sets (Tables S2  and S4 ) and were calculated to compare each metabolite and CpG site ( Figure S1 ). Many bivariate correlations were significant, however, imprinted gene loci, IGF2 and H19 had strikingly few significant correlations in this initial analysis ( Figure S2) . Thus, based on this analysis alone, it appears that global methylation and non-imprinted gene methylation are associated with maternal metabolites but that imprinted gene loci are not impacted by these factors.
False Discovery Rate Correction. To correct for multiple testing among metabolites in related pathways and methylation sites within the same gene loci, the Benjamini-Hochberg method was used to calculate adjusted p-values for false discovery rate (FDR) (27). Statistical significance was determined by resulting adjusted p-values < 0.05. These analyses were used to assess the correlations between maternal and infant methylome and metabolome in the 1st trimester and at delivery. 
